Establishment of prognostic models for adenocarcinoma of oesophagogastric junction patients with neoadjuvant chemoradiotherapy: a real-world study

被引:9
|
作者
Du, Rongxu [1 ]
Ming, Jiao [1 ]
Geng, Jianhao [1 ]
Zhu, Xianggao [1 ]
Zhang, Yangzi [1 ]
Li, Shuai [1 ]
Liu, Zhiyan [1 ]
Wang, Hongzhi [1 ]
Wang, Zhilong [2 ]
Tang, Lei [2 ]
Zhang, Xiaotian [3 ]
Wu, Aiwen [4 ]
Bu, Zhaode [4 ]
Yan, Yan [5 ]
Li, Zhongwu [6 ]
Li, Yongheng [1 ]
Li, Ziyu [4 ]
Wang, Weihu [1 ]
机构
[1] Peking Univ Canc Hosp & Inst, Dept Radiat Oncol, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing 100142, Peoples R China
[2] Peking Univ Canc Hosp & Inst, Dept Med Imaging, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing 100142, Peoples R China
[3] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing 100142, Peoples R China
[4] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Surg, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing 100142, Peoples R China
[5] Peking Univ Canc Hosp & Inst, Endoscopy Ctr, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing 100142, Peoples R China
[6] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Dept Pathol, Beijing 100142, Peoples R China
关键词
Adenocarcinoma of the oesophagogastric junction; Neoadjuvant chemoradiotherapy; Pathologic response; Inflammation-based and nutrition-related factors; Prediction models; GASTRIC-CANCER; PREOPERATIVE CHEMORADIOTHERAPY; CHEMOTHERAPY; SURGERY; CARCINOMA; ESOPHAGUS; CARDIA;
D O I
10.1186/s13014-022-02016-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Multimodal therapies based on surgical resection have been recommended for the treatment of adenocarcinoma of the oesophagogastric junction (AEG). We aimed to evaluate prognostic factors in AEG patients receiving neoadjuvant chemoradiotherapy and to build predictive models. Methods T3 - T4N + M0 AEG patients with resectable Siewert type II/III tumours were enrolled in this study. All patients underwent neoadjuvant chemoradiation, followed by radical surgery or systemic therapy according to clinical response. Survival analysis was performed using the Kaplan-Meier method; multivariate analysis using the Cox proportional hazards method was also conducted. The Harrell concordance index (C-index) was used to test the prognostic value of models involving prognostic factors, and consistency between actual and predicted survival rates was evaluated by calibration curves. Results From February 2009 to February 2018, 79 patients were treated with neoadjuvant chemoradiotherapy; 60 patients of them underwent radical surgery. The R0 resection rate was 98.3%, and 46.7% of patients achieved a major pathologic response (MPR), namely, a residual tumour issue less than 10%. The 5-year overall survival (OS) rate was 63%, and the 5-year progression-free survival (PFS) rate was 48%. The incidence of grade 3 complications was 21.5%, and no grade 4 complications were reported. According to the results of univariate and multivariate analyses, we included the neutrophil-lymphocyte ratio (NLR), prognostic nutrition index (PNI), eosinophilic granulocyte (EOS) and postoperative pathologic stage in nomogram analysis to establish prediction models for OS and PFS; the C-index of each model was 0.814 and 0.722, respectively. Both the C-index and calibration curves generated to validate consistency between the actual and predicted survival indicated that the models were well calibrated and of good predictive value. Conclusions AEG patients achieved favourable downstaging and pathologic response after neoadjuvant chemoradiation, with acceptable adverse effects. Inflammation-based and nutrition-related factors and postoperative pathologic stage had a significant influence on OS and PFS, and the predictive value was verified through prognostic models.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Establishment of prognostic models for adenocarcinoma of oesophagogastric junction patients with neoadjuvant chemoradiotherapy: a real-world study
    Rongxu Du
    Jiao Ming
    Jianhao Geng
    Xianggao Zhu
    Yangzi Zhang
    Shuai Li
    Zhiyan Liu
    Hongzhi Wang
    Zhilong Wang
    Lei Tang
    Xiaotian Zhang
    Aiwen Wu
    Zhaode Bu
    Yan Yan
    Zhongwu Li
    Yongheng Li
    Ziyu Li
    Weihu Wang
    Radiation Oncology, 17
  • [2] Neoadjuvant concurrent chemoradiotherapy combined with immunotherapy in the treatment of adenocarcinoma of the oesophagogastric junction: A phase II study
    Du, R.
    Ming, J.
    Geng, J.
    Sui, X.
    Li, S.
    Liu, Z.
    Zhu, X.
    Cai, Y.
    Wang, Z.
    Tang, L.
    Zhang, X.
    Peng, Z.
    Yan, Y.
    Li, Z.
    Peng, Y.
    Wu, A.
    Li, Y.
    Li, Z.
    Wang, W.
    Ji, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1104 - S1104
  • [3] Prognostic impact of sarcopenia in patients with locally advanced adenocarcinoma of the esophagogastric junction treated with neoadjuvant chemoradiotherapy
    Ming, Jiao
    Du, Rongxu
    Geng, Jianhao
    Li, Shuai
    Liu, Zhiyan
    Cai, Yong
    Zhu, Xianggao
    Zhang, Yangzi
    Wang, Hongzhi
    Wang, Zhilong
    Tang, Lei
    Zhang, Xiaotian
    Peng, Zhi
    Wu, Aiwen
    Bu, Zhaode
    Peng, Yifan
    Yan, Yan
    Li, Zhongwu
    Li, Yongheng
    Li, Ziyu
    Wang, Weihu
    FRONTIERS IN NUTRITION, 2023, 10
  • [4] Survival outcomes of neoadjuvant and adjuvant chemoradiotherapy for locally advanced adenocarcinoma of the oesophagogastric junction: a retrospective cohort study using the SEER database
    Zhang, Fan
    Feng, Xingyu
    Li, Yong
    Yan, Juan
    Zhang, Zhilin
    Song, Xiao
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (01) : 26 - 39
  • [5] Prognostic significance of the location of metastatic lymph nodes in patients with adenocarcinoma of the oesophagogastric junction
    Liu, Jun-Feng
    Jiang, Tao
    Shi, Zhi-Hua
    Liu, Xin-Bo
    ANZ JOURNAL OF SURGERY, 2018, 88 (03) : 218 - 222
  • [6] Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction
    Zhu, Mojun
    Chen, Chunhua
    Foster, Nathan R.
    Hartley, Christopher
    Mounajjed, Taofic
    Salomao, Marcela A.
    Fruth, Briant F.
    Beamer, Staci E.
    Kim, Yohan
    Harrington, Susan M.
    Pitot, Henry C.
    Sanhueza, Cristobal T.
    Feng, Yening
    Herrmann, Joerg
    McWilliams, Robert R.
    Lucien, Fabrice
    Huang, Bing Q.
    Ma, Wen Wee
    Bekaii-Saab, Tanios S.
    Dong, Haidong
    Wigle, Dennis
    Ahn, Daniel H.
    Hallemeier, Chris L.
    Blackmon, Shanda
    Yoon, Harry H.
    CLINICAL CANCER RESEARCH, 2022, 28 (14) : 3021 - 3031
  • [7] Adjuvant treatment after neoadjuvant chemoradiotherapy and surgery in patients with esophageal squamous cell carcinoma: a real-world study
    Geng, Yuxin
    Zhao, Junfeng
    Li, Ying
    Li, Yintao
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
  • [8] Impact of the Siewert Classification on the Outcome of Patients Treated by Preoperative Chemoradiotherapy for a Nonmetastatic Adenocarcinoma of the Oesophagogastric Junction
    Moureau-Zabotto, Laurence
    Teissier, Eric
    Cowen, Didier
    Azria, David
    Ellis, Steve
    Resbeut, Michel
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2015, 2015
  • [9] Neoadjuvant Chemotherapy or Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: Real-World Data Comparison from A Japanese Nationwide Study
    Okamura, Akihiko
    Watanabe, Masayuki
    Okui, Jun
    Matsuda, Satoru
    Takemura, Ryo
    Kawakubo, Hirofumi
    Takeuchi, Hiroya
    Muto, Manabu
    Kakeji, Yoshihiro
    Kitagawa, Yuko
    Doki, Yuichiro
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (09) : 5885 - 5894
  • [10] Chemoradiotherapy versus surgery after neoadjuvant chemoimmunotherapy in patients with stage III NSCLC: a real-world multicenter retrospective study
    Guan, Song
    Sun, Jifeng
    Wang, Yuan
    Han, Sibei
    Chen, Chen
    Yue, Dongsheng
    Huang, Yubei
    Ren, Kai
    Wang, Jun
    Wang, Jun
    Zhao, Lujun
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (07)